Aloxi Injection 2004 Sales Results Expected to Exceed Previous Guidance.Business Editors/Health/Medical Writers MINNEAPOLIS--(BUSINESS WIRE)--March 17, 2004 MGI MGI Mouse Genome Informatics MGI Modular Gateway Interface MGI McKinsey Global Institute MGI Military Geographic Information MGI Marine Geological Institute MGI Policy on the Management of Government Information (Canada) PHARMA, INC inc - /ink/ increment, i.e. increase by one. Especially used by assembly programmers, as many assembly languages have an "inc" mnemonic. Antonym: dec. . (Nasdaq:MOGN) today announced that it expects sales of Aloxi(TM) injection for the first quarter of 2004 to exceed previous guidance of $12 million. MGI PHARMA now anticipates sales of Aloxi injection to be in the range of $15 million to $17 million for the first quarter. Recent trends indicate that 2004 annual sales of Aloxi injection could exceed prior guidance and range from $100 million to $110 million. "More than 125,000 patient treatments with Aloxi injection have occurred since its launch in September 2003," said Lonnie Moulder moul·der v. Chiefly British Variant of molder. moulder or US molder Verb to crumble or cause to crumble, as through decay: , president and chief executive officer of MGI PHARMA. "We are very pleased that the launch of Aloxi is off to a great start, and believe that this sales performance positions us well to continue executing on our business development initiatives." MGI PHARMA plans to issue its first quarter 2004 financial results news release, including updated annual 2004 guidance, before the market opens on Wednesday, April 14, 2004. Following this news release, the Company will broadcast its first quarter 2004 financial results conference call live over the Internet on Wednesday, April 14, 2004 at 1:00 p.m. Eastern Time. All interested parties are welcome to access the webcast via the Company's Web site at www.mgipharma.com. About MGI PHARMA MGI PHARMA, INC. is an oncology-focused biopharmaceutical company that acquires, develops and commercializes proprietary products that address the unmet needs of cancer patients. MGI has a portfolio of proprietary pharmaceuticals, and intends to become a leader in oncology. MGI markets Aloxi(TM) (palonosetron hydrochloride palonosetron hydrochloride Aloxi Pharmacologic class: Selective serotonin subtype 3 (5-HT3) receptor antagonist Therapeutic class: Antiemetic Pregnancy risk category B ) injection, Salagen(R) Tablets (pilocarpine pilocarpine (pīlōkär`pēn), naturally occurring alkaloid obtained from plants of the genus Pilocarpus (family Rutaceae). hydrochloride hydrochloride /hy·dro·chlo·ride/ (-klor´id) a salt of hydrochloric acid.hy·dro·chlo·ride n. A compound resulting from the reaction of hydrochloric acid with an organic base. ) and Hexalen(R) (altretamine) capsules in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. . The Company directly markets its products in the U.S. and collaborates with partners in international markets. For more information about MGI, please visit the Company's Web site at www.mgipharma.com. This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These statements are typically preceded by words such as "believes," " expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of MGI PHARMA's future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the Company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, continued sales of MGI PHARMA's marketed products; development or acquisition of additional products; reliance on contract manufacturing; changes in strategic alliances; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission including in the Risks Related to Our Business section of its most recently filed Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. . MGI PHARMA undertakes no duty to update any of these forward-looking statements to conform them to actual results. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion